Two Ongoing Clinical Trials of IPI-145 for Hematologic Malignancies
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.
DUO
- DUO is a randomized, phase III trial comparing IPI-145 to ofatumumab for patients with relapsed or refractory CLL or SLL.
- Ofatumumab is a CD20-directed cytolytic monoclonal antibody approved for the treatment of CLL.
- Patients in this trial are randomized 1:1 and are able to cross over.
DYNAMO
- DYNAMO is a single-arm, phase II trial of patients with non-Hodgkin lymphoma that are no longer responding to rituximab or chemotherapy.
- There is currently no established therapy for this group of patients.
<<<
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
